BUZZ-Jefferies sees low risk of earnings impact for CSL from potential US regulatory review
Reuters
Jan 29
BUZZ-Jefferies sees low risk of earnings impact for CSL from potential US regulatory review
** Jefferies expects minimal risk of meaningful earnings impact for CSL CSL.AX as various U.S. regulatory reviews including CMS programs are undertaken
** Brokerage says there is ongoing lack of regulatory focus on plasma - key product for CSL - compared with other drug categories
** Adds plasma industry looks "rational", with expansion in blood-collection centres, inventory and capacity in line with demand, providing further upside for CSL
** Jefferies maintains "buy" call for CSL, price target of A$240
** CSL fell 38.7% last year
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.